Protagonist Therapeutics, Inc. — 2020 Q1 Form 10-Q Summary
Business context and reporting period
Protagonist is a clinical-stage biopharmaceutical company developing peptide-based medicines. Its principal programs were PTG-300 for blood disorders, PTG-200 and PN-943 for inflammatory bowel disease, and earlier-stage discovery programs. The filing covers the unaudited three months ended March 31, 2020, compared with the three months ended March 31, 2019, and was filed May 7, 2020.
Financial performance and liquidity
| Metric | Q1 2020 | Q1 2019 | Change |
|---|---|---|---|
| License and collaboration revenue | $3.6 million | $1.6 million | +$2.1 million, or 134% |
| Research and development expense | $18.8 million | $12.4 million | +$6.3 million, or 51% |
| General and administrative expense | $4.6 million | $3.8 million | +$0.8 million, or 22% |
| Loss from operations | $(19.7) million | $(14.6) million | Loss increased $5.0 million |
| Net loss | $(20.1) million | $(14.1) million | Loss increased $6.0 million, or 42% |
| Basic and diluted loss per share | $(0.72) | $(0.58) | Lower by $0.14 |
| Cash used in operating activities | $(15.8) million | $(16.7) million | Use decreased $0.8 million |
Revenue consisted entirely of related-party license and collaboration revenue, primarily under the Janssen agreement. The increase reflected additional services and deliverables following the 2019 amendment and proportional-performance revenue recognition. The agreement’s estimated transaction price was $113.6 million at March 31, 2020, including the $5.0 million milestone triggered by nomination of a second-generation compound.
Approximate operating and net margins were negative 540% and negative 551%, respectively, based on reported revenue; these margins are not comparable to product-company gross margins because the company has no product sales and revenue is collaboration-based.
At March 31, 2020, cash and cash equivalents were $60.2 million, marketable securities were $57.3 million, and total cash, cash equivalents and marketable securities were approximately $117.5 million. Total assets were $134.9 million, stockholders’ equity was $62.7 million, and accumulated deficit was $237.7 million.
Net cash increased by $27.2 million during the quarter, primarily because $42.7 million of investing cash inflow from marketable-security maturities exceeded operating cash use. This increase does not represent operating profitability. The company stated that existing liquidity and available debt capacity were expected to fund operations for at least the next 12 months, but it expects to require substantial additional capital in the future.
Debt and financing
- Long-term debt was $9.8 million net at March 31, 2020, representing a $10.0 million term loan funded in October 2019.
- The term-loan facility permits up to $50.0 million of aggregate borrowings, with an additional $40.0 million available subject to clinical milestones, minimum-cash requirements and other conditions.
- The funded loan bears interest at prime plus 2.91%, subject to a 4.94% prime-rate floor, and matures October 1, 2023. The reported rate was 7.85%.
- The company was in compliance with its debt covenants, and no event of default had occurred as of March 31, 2020.
- The debt is secured by substantially all company assets other than intellectual property and certain excluded property, and the agreement restricts actions including additional indebtedness, dividends and certain corporate transactions.
- No securities were sold under the 2019 Form S-3 or related ATM facility through March 31, 2020. The company reported $72.0 million of remaining availability under the 2017 Form S-3.
Material changes versus the prior comparable period
- R&D spending increased 51%, led by higher costs for PN-943, PTG-300, PTG-200 and preclinical discovery activities. PTG-100 spending declined as development was wound down.
- PTG-300 development shifted toward polycythemia vera and hereditary hemochromatosis. The company discontinued development for beta-thalassemia and myelodysplastic syndromes.
- PN-943’s IND became effective in January 2020, but the company suspended timing guidance for its planned Phase 2 ulcerative-colitis study.
- Because of COVID-19, the company suspended guidance on completion timing for the Janssen-supported PTG-200 Phase 2 Crohn’s disease study.
- Interest expense increased to $0.2 million because the term loan was not outstanding in Q1 2019; interest income declined with lower interest rates and lower invested balances.
- Shares outstanding increased to 27.4 million at March 31, 2020 from 27.2 million at December 31, 2019, primarily through employee equity programs.
Guidance, outlook, risks and unusual items
- Management expects continuing operating losses and no sustained profitability in the foreseeable future. Future funding needs depend on clinical progress, trial costs, regulatory outcomes, collaboration milestones and the impact of COVID-19.
- COVID-19 could delay patient enrollment, clinical-site activities, trial monitoring, regulatory interactions, manufacturing and supply chains, and collaboration activities. The ultimate financial effect remained uncertain.
- The Janssen collaboration is a major source of potential future value and funding, but future milestone, opt-in and royalty payments are contingent on clinical and commercial progress. Janssen may terminate or discontinue programs, which could materially reduce future revenue and require Protagonist to fund development independently.
- On May 7, 2020, after the quarter ended, the company approved a reduction in force affecting approximately 12% of employees. It expected approximately $0.3 million of cash severance and benefit costs, substantially in Q2 2020.
- The company has no approved products, no product-sales revenue and no registrational or pivotal clinical trials. Clinical, regulatory, manufacturing, intellectual-property, financing and commercialization risks remain substantial.
- No material legal proceedings were reported. Management concluded that disclosure controls and procedures were effective at the reasonable-assurance level, with no material changes in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether the stated cash runway remains adequate after COVID-19-related delays, the reduction in force and changes in clinical spending.
- The timing, enrollment, safety and efficacy results of PTG-300, PN-943 and the Janssen-supported PTG-200 studies.
- Whether Janssen achieves the milestones and exercises the continuation or opt-in rights that could generate additional payments.
- The availability and conditions for drawing the remaining $40.0 million under the term-loan facility, including clinical milestones and minimum-cash requirements.
- The company’s future financing requirements, potential equity dilution and compliance with secured-debt covenants.
- The accuracy of collaboration-revenue estimates, including cost-to-complete assumptions and variable consideration that could cause future cumulative revenue adjustments.